SFDA Southern Medical Economics Research Institute (hereinafter referred to as the Southern Institute) announced on the 18th that the top 100 Chinese pharmaceutical industry & rdquo; 2011，China Resources Medicine、Shanghai Medicine、Stone Medicine Group、Harbin Pharmaceutical Group、Yangzijiang Pharmaceutical、Correction Pharmaceutical、North China Pharmaceutical、Steps Pharmaceutical、Tongrentang、Tianjin Medicine ranks the top ten in the top 100 list。
Analysis report of the Southern Institute，2011，The overall scale of the top 100 domestic pharmaceutical industry continues to increase，Total sales revenue is 55.2416 billion yuan，increased by 27.01%year -on -year，increased by 1.19 percentage points compared with the same period of 2010 (28.20%)。
China Resources Pharmaceutical Group ranks first in the list
Among the top 100 pharmaceutical industry，There are 11 companies with a size of more than 10 billion yuan，23 companies with 5 billion to 10 billion yuan，51 companies from 2 billion to 5 billion yuan，There are 15 companies with the size of the enterprise below 2 billion yuan。The rapid development of medium -sized enterprises brings a steady stream of driving force，Enterprises between 200 and 5 billion yuan and 5 billion to 10 billion yuan increased three and two.。China Resources Pharmaceutical Group appeared on the stake betting apptop of stake sports betting appthe list for the first time in the name of the group。
After the reorganization of China Run Group in 2011，Around building a business circulation platform、Traditional Chinese Medicine Platform、Large infusion platform，Vigorously promote internal business integration，Created the pattern of the group。
SFDA Director Tao Jianhong, deputy director of the Southern Medical Economics Research Institute, pointed out & ldquo;，The number of pharmaceutical groups over 10 billion yuan increased more than doubled from 2010。And the industry concentration has increased significantly。& rdquo; She said，The top 50 sections of the top 50 drugs in 2011 accounted for the top 100 sections of the top 50 and the proportion of the top 100 and the national pharmaceutical industry. Compared with 2010, it increased to varying degrees。Where，The concentration of the top 5 companies in the top 5 companies has increased by 1.13 percentage points，reached 19.20%; the concentration of the overall concentration of the pharmaceutical industry has increased by 0.63 percentage points，reaches 8.48%。
The first disclosure of the ranking of innovative pharmaceutical companies
Except for the top 100 pharmaceutical industry，The Institute of Southern Medical Economics also announced the first ten most innovative pharmaceutical companies in China。Hengrui、Pioneer、The top three of Tiansi ranking。
Tao Jianhong thinks，Innovative enterprises can be divided into three echelons，First is a pioneer original pharmaceutical company，For example, the pilot pharmaceutical industry and Hengrui Pharmaceutical that successfully declared in the 1.1 new drug in 2011; the second is the backbone of high -efficiency learning，For example, Lizhu Pharmaceutical is currently in the field of monoclonal anti -resistance，The active layout of Haizheng Pharmaceutical and Huahai Pharmaceutical in the field of characteristic raw materials and drugs; the third is integrated innovation，Many of the Chinese medicine companies in the top 100 are outstanding，For example，and Guizhou Bailing's force in the field of ethnic medicine。
Hengrui Pharmaceutical is known as & ldquo; Currently, the company with the most new drugs in A -share listed companies & rdquo;My stake betting app，Despite stake online sports bettingthe low -key style，But the company's 2011 annual report still cannot stop its R & D edge: a new type of new medicine Ericibab has been approved，Application of SHR 1258 and other clinical projects 6、Non -Tiscs and other production projects，Innovation medicine Apatinib completed the phase III clinical study of lung cancer; Ilide Kangju was approved by the United States to be listed in a milestone。
It is reported，Xianmin Pharmaceuticals in 2010，A total of eight types of innovative drugs entered and will enter the clinical research stage，This is the first company in more than 4,000 pharmaceutical companies in China to make such progress; 2011，Innovative drugs for the treatment of strokes to complete the first phase of clinical in Australia，This is also the first innovative drug injection from China to conduct clinical research in Western countries。Relevant person in charge of Xianyin Pharmaceutical told reporters，Xianmin Pharmaceutical will continue to increase the investment in new drug research and development，Input ratio is gradually increased to 10%of sales revenue，Continue to take & ldquo; independent research and development and cooperate with the internationally renowned R & D platform to jointly develop & rdquo;。The direction of R & D and innovation will still be concentrated in the field of disease treatment with high incidence or high mortality and more effective drug needs，Therefore, the research and development field will continue to focus on anti -tumor、Cardiovascular and cerebrovascular、Anti -infection、Anti -inflammatory analgesic and other disease treatment fields。
Capital operation pace accelerates
The Economic Research Office of the Southern Medical Economics Research Institute pointed out the analysis of the top 100 pharmaceutical industry in 2011，The pace of capitalization operation of pharmaceutical companies in 2011。
With the maturity of my country's capital market and the active industrial capital，More and more companies are ranked among listed companies。2011，There are 23 newly listed pharmaceutical companies，Mainly concentrated on 7 small and medium -sized enterprise boards，16 GEM。Among the top 100 companies stake betting appon the stake sports betting apptop 100 drugs，With 70 listed companies (including overseas listing，The same below)，There are 929 subsidiaries who have been incorporated into the scope of the merged scope by listed companies。
but，The top 100 list shows that the utilization of corporate funds is reduced。2011，The overall account receivable cycle of the top 100 pharmaceutical companies is 54.8 days，Extended 14.4 days than the national average level (40.4 days) of the national pharmaceutical industry (40.4 days) in the same period，Compared with 2010，In 2011, the account receivable cycle of the Top 100 companies was extended by 10.1 days。Top 100 companies have the advantages of capital scale，Dilemma with no capital tension or shortage，But how can I better shorten the payment of the payment back，Realize effective business behavior，The utilization of funds is a question that the company should focus on thinking。
In addition，There is also a major feature of the top 100 list. It is a disadvantaged group for state -owned enterprises。The top 100 companies in the pharmaceutical industry are mainly based on joint -stock systems, Hong Kong, Macao and Taiwan, and foreign -invested economy types.，The total amount of two types of enterprises accounts for 80.71%of the total amount of the top 100，3.42 percentage points increased by the level in 2010。2011，There are 14 multinational pharmaceutical companies entering the top 100 pharmaceuticals at Huazi Company，Among them, there are 11 pharmaceutical subsidiaries established by Fortune 500 companies in the Fortune World。
Tao Jianhong pointed out，In the future, domestic pharmaceutical companies should pay more attention to changes in the demand structure，Only new opportunities。According to an introduction，The future medication structure will be roughly presented in several aspects: First, specialization，With the improvement of medical insurance level，Drug demand for old people will increase significantly，Need to develop an appropriate dosage type or specification for the elderly and children; the second is composite，For example, the new compound reciprocity of existing drugs，Reduce the frequency of medication for patients，My stake betting appThere stake betting appare also multi -link vaccines that prevent a variety of diseases、The occurrence of prevention and therapeutic and therapeutic vaccines; the third is rationalization，Abuse of drugs such as antibiotics and hormones will be significantly reduced，The use of targeted therapy technology reduces the side effects of drugs、Analysis of Pharmaceutical Guidance Prescription、Clinical Pharmaceutical Monitoring is even more valued; fourth is defense，Prevention of slow diseases will be highly valued，Some preventive、Self -care for health care will be developed; fifth is step gradient，The clinical path of treatment is clearer，In the treatment of chronic diseases，For example, hypertension and diabetes will have a clear guidelines for ladder drugs; six are personalized，Life Science Promotion of Genome Research，It is possible to realize personalized treatment solutions in the future。
